

Charge

Develop recommendations for federal agencies, policy makers, societies, and researchers about the relevance of Generative AI (Gen AI) to biological and biomedical science. Educate the scientific community (including the workforce) about the risks and benefits of Gen AI in the biological and biomedical sciences and how to best leverage Gen AI tools to advance science. Identify opportunities for FASEB and FASEB member societies to use Gen AI to meet our shared missions.

Objectives

- 1) Develop a report with recommendations on the appropriate and responsible use of Gen AI in routine research activities, including lab tech, research, career development, meeting programming, peer review in publishing and grant review (copyright implications, administration, policy).
- 2) Create a guide that identifies existing educational resources, webinars, white papers, , examples of positive use cases, suggested toolkits, etc. related to appropriate/ethical usage of Gen AI in the biological/biomedical sciences
- 3) Identify potential FASEB and society applications of Gen AI that can enhance mission, improve staff scope, expand member engagement, and increase efficiency of operations.
- 4) Identify opportunities to generate revenue for FASEB related to use of Gen AI in the biological/biomedical sciences and submit recommendations to the FASEB Board for further consideration.

Members

Size: 5-7 members plus chair/vice chair (total 7-9)

Focus on early career researchers, geographic and gender diversity, representation spanning basic research and clinical/healthcare communities

- FASEB Society affiliated members
- FASEB Society affiliated staff
- Outside participants (Gen AI/technical expertise, Legal/Intellectual Property, IT, ethicists)

Voting:

Non-Voting:

Member Selection

- Open call for nominations from member societies (January 9 – January 24, 2024)
- Targeted outreach to fill gaps (January 24 – January 31, 2024)

Time Commitment

- 1.5 hours/month
- 12 months

Timeline

- Q1: Develop task force work plan/schedule; update to Board in March
- Q2: Update to Board in June
- Q3: Update to Board in September (preview of draft report)
- Q4: Final report to Board in December